CStone Pharmaceuticals ('CStone,' HKEX: 2616), an innovation-driven biopharmaceutical company focused on the research and development of therapies for oncology, immunology, inflammation, and other key ...
Olverembatinib, an investigational multikinase inhibitor (approved in China for CML), inhibits Src-family kinases (e.g., Lyn, Fyn, YES1) and BTK, which are essential for B-cell receptor (BCR) ...
Revolution Medicine has wowed investors and analysts by announcing dazzling data from its Phase III RASolute 302 trial ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results